ArticleFrontiers in oncology2019
A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.
7 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 42 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05289908 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation
Phase I/II Clinical Trial of Intrathecal Pemetrexed as First Line Intrathecal Chemotherapy in Patients With Leptomeningeal Metastasis
An Open-label, Randomized, Multicenter Trial of Intrathecal-pemetrexed Combined With Concurrent Involved-field Radiotherapy and Intrathecal-pemetrexed Alone in Patients With Leptomeningeal Metastasis From Solid Tumors
An Open-label, Single-arm, Phase II Trial of Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After a Double Dose of Third-generation TKIs, Including Osimertinib
A Clinical Trial of Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
NCT06462092 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase I/II Clinical Study of Sacituzumab Govitecan Combined With Intrathecal Chemotherapy for the Treatment of Leptomeningeal Metastases From Her2-negative Breast Cancer
NCT06462222 phase1 / phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study
NCT06762080 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation
Intrathecal Administration of PD-1/CTLA-4 Bispecific Antibody Plus Pemetrexed in Patients With Leptomeningeal Metastasis From Solid Tumors: A Phase I/II Study
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A comparative study of Ommaya reservoir versus lumbar puncture for intrathecal chemotherapy in patients with leptomeningeal metastasis: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients.Frontiers in oncology · 2025Pooled it
- Pooled it
- [Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Trial
- Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.Journal of neuro-oncology · 2025Trial
- Trial
- Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.Thoracic cancer · 2021Trial
- Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.Nature cancer · 2026Article
- Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.BMC cancer · 2026Article
- Multimodality salvage treatment incorporating ivonescimab plus chemotherapy for EGFR-mutated NSCLC with leptomeningeal metastases after dose-escalated third-generation EGFR-TKI failure: a retrospective study.Frontiers in immunology · 2026Article
- Advances in Ommaya reservoir-based intrathecal therapy for leptomeningeal metastasis from non-small cell lung cancer: a systematic review.Frontiers in oncology · 2026Review
- [Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Intrathecal pemetrexed in patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant refractory leptomeningeal metastasis lung adenocarcinoma: a retrospective study.Journal of thoracic disease · 2025Article
- Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study.The oncologist · 2025Article
- Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.Thoracic cancer · 2025Article
- Article
- Leptomeningeal Disease: Current Approaches and Future Directions.Current neurology and neuroscience reports · 2025Review
- Case Report: Extended survival in KRAS-G12V NSCLC with leptomeningeal metastasis through integrated intrathecal chemotherapy and systemic therapies.Frontiers in pharmacology · 2025Article
- Intrathecal pemetrexed chemotherapy combined with systemic therapy in patients with non-small cell lung cancer and leptomeningeal metastases: a retrospective study.Frontiers in oncology · 2025Review
- Intrathecal administration of PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from breast cancer: a case report.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Zhenyu PanDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Guozi YangDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, China.
Wei LiCancer Center, The First Hospital of Jilin University, Changchun, China.
Yu LiDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Pengxiang GaoDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Tongchao JiangDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Yanan SunDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Lihua DongDepartment of Radiation-Oncology, The First Hospital of Jilin University, Changchun, China.
Yuanyuan SongDepartment of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.
Gang ZhaoDepartment of Neuro-Oncological Surgery, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
intrathecal chemotherapyleptomeningeal metastasesnon-small cell lung cancerpemetrexedrefractory
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05289908ClinicalTrials.gov
NCT05305885ClinicalTrials.gov
NCT06296745ClinicalTrials.gov
NCT06304441ClinicalTrials.gov
NCT06462092ClinicalTrials.gov
NCT06462222ClinicalTrials.gov
and 1 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.